TO IMPROVE CANCER PATIENT OUTCOMES BY ADVANCING THE SCIENCE, DEVELOPMENT AND APPLICATION OF CANCER IMMUNOLOGY AND IMMUNOTHERAPY THROUGH OUR CORE VALUES OF INTERACTION/INTEGRATION, INNOVATION, TRANSLATION, DIVERSITY AND INCLUSION AND LEADERSHIP IN THE FIELD. SITC AIMS TO MAKE CANCER IMMUNOTHERAPY A STANDARD OF CARE AND THE WORD "CURE" A REALITY FOR CANCER PATIENTS EVERYWHERE.
Executive compensation
Form 990 · Schedule J · 3 reported individuals · Filing year 2024
| Position | Total |
|---|---|
Director board member | $2k $2k |
Director board member | $2k $2k |
Director board member | $1k $1k |
Teal figures restate each filed amount in 2026 dollars.
Estimated with BLS CPI-U for the Midwest region, restating filed pay into May 2026 dollars. A restatement of past pay, not current or projected pay.
Plus 10 unpaid individuals.
Revenue and expenses over time
SOCIETY FOR IMMUNOTHERAPY OF CANCER INC reported revenue and expenses across 2 filing years.
Compare any role, sector, or revenue band
Build your own benchmark from millions of reported positions.